These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 33152708)

  • 1. Cost-Effectiveness of Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer.
    Wu B; Shi L
    J Natl Compr Canc Netw; 2020 Nov; 18(11):1528-1536. PubMed ID: 33152708
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-Effectiveness and Net Monetary Benefit of Olaparib Maintenance Therapy Versus No Maintenance Therapy After First-line Platinum-based Chemotherapy in Newly Diagnosed Advanced BRCA1/2-mutated Ovarian Cancer in the Italian National Health Service.
    Armeni P; Borsoi L; Fornaro G; Jommi C; Colombo N; Costa F
    Clin Ther; 2020 Jul; 42(7):1192-1209.e12. PubMed ID: 32591103
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PARP inhibitor maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer: a cost-effectiveness analysis.
    Smith HJ; Walters Haygood CL; Arend RC; Leath CA; Straughn JM
    Gynecol Oncol; 2015 Oct; 139(1):59-62. PubMed ID: 26303225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of olaparib as a maintenance treatment for women with newly diagnosed advanced ovarian cancer and BRCA1/2 mutations in the United States.
    Muston D; Hettle R; Monberg M; McLaurin KK; Gao W; Swallow E; Zhang S; Kalemaj I; Signorovitch J; Moore K
    Gynecol Oncol; 2020 Nov; 159(2):491-497. PubMed ID: 32951894
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Maintenance Olaparib for Germline
    Golan T; Hammel P; Reni M; Van Cutsem E; Macarulla T; Hall MJ; Park JO; Hochhauser D; Arnold D; Oh DY; Reinacher-Schick A; Tortora G; Algül H; O'Reilly EM; McGuinness D; Cui KY; Schlienger K; Locker GY; Kindler HL
    N Engl J Med; 2019 Jul; 381(4):317-327. PubMed ID: 31157963
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Olaparib as first line in BRCA-mutated advanced ovarian carcinoma: Is it cost-effective in Spain?
    Moya-Alarcón C; González-Domínguez A; Ivanova-Markova Y; Gimeno-Ballester V; Barretina-Ginesta MP; Pérez-Fidalgo JA; Redondo A
    Gynecol Oncol; 2022 Feb; 164(2):406-414. PubMed ID: 34844775
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Olaparib for Maintenance Treatment of BRCA 1 or 2 Mutated, Relapsed, Platinum-Sensitive Ovarian, Fallopian Tube and Peritoneal Cancer in People Whose Relapsed Disease has Responded to Platinum-Based Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Tappenden P; Harnan S; Ren S; Thokala P; Wong R; Mukuria C; Green C; Pledge S; Tidy J
    Pharmacoeconomics; 2017 Jan; 35(1):97-109. PubMed ID: 27506954
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of Maintenance Therapy Based on Molecular Classification Following Treatment of Primary Epithelial Ovarian Cancer in the United States.
    Penn CA; Wong MS; Walsh CS
    JAMA Netw Open; 2020 Dec; 3(12):e2028620. PubMed ID: 33295974
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-Effectiveness of Niraparib and Olaparib as Maintenance Therapy for Patients with Platinum-Sensitive Recurrent Ovarian Cancer.
    Zhong L; Tran AT; Tomasino T; Nugent E; Smith JA
    J Manag Care Spec Pharm; 2018 Dec; 24(12):1219-1228. PubMed ID: 30479195
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Olaparib not cost-effective as maintenance therapy for platinum-sensitive, BRCA1/2 germline-mutated metastatic pancreatic cancer.
    Mehra T; Lupatsch JE; Kössler T; Dedes K; Siebenhüner AR; von Moos R; Wicki A; Schwenkglenks ME
    PLoS One; 2024; 19(4):e0301271. PubMed ID: 38573891
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-Effectiveness Analysis of Maintenance Olaparib in Patients with Metastatic Pancreatic Cancer and a Germline BRCA1/2 Mutation Based on the POLO Trial.
    Zhan M; Zheng H; Yang Y; He Z; Xu T; Li Q
    Cancer Manag Res; 2020; 12():12919-12926. PubMed ID: 33364840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is olaparib cost effective in metastatic castration-resistant prostate cancer patients with at least one favorable gene mutation in
    Li Y; Lin S; Zhong L; Luo S; Huang X; Huang X; Dong L; Xu X; Weng X
    Pharmacogenomics; 2021 Aug; 22(13):809-819. PubMed ID: 34517749
    [No Abstract]   [Full Text] [Related]  

  • 13. Cost-effectiveness of olaparib maintenance therapy when used with and without restriction by
    Cheng LJ; Wong G; Chay WY; Ngeow J; Tan Y; Soon SS; Aziz MIA; Pearce F; Ng K
    Expert Rev Pharmacoecon Outcomes Res; 2021 Jun; 21(3):441-448. PubMed ID: 33593205
    [No Abstract]   [Full Text] [Related]  

  • 14. Cost-Effectiveness Analysis of Olaparib Maintenance Treatment for Germline BRCA-Mutated Metastatic Pancreatic
    Li N; Zheng H; Huang Y; Zheng B; Cai H; Liu M
    Front Pharmacol; 2021; 12():632818. PubMed ID: 33959007
    [No Abstract]   [Full Text] [Related]  

  • 15. Cost-effectiveness of BRCA1 and BRCA2 mutation testing to target PARP inhibitor use in platinum-sensitive recurrent ovarian cancer.
    Secord AA; Barnett JC; Ledermann JA; Peterson BL; Myers ER; Havrilesky LJ
    Int J Gynecol Cancer; 2013 Jun; 23(5):846-52. PubMed ID: 23666017
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of
    Saito S; Nakazawa K; Nagahashi M; Ishikawa T; Akazawa K
    Per Med; 2019 Nov; 16(6):439-448. PubMed ID: 31692405
    [No Abstract]   [Full Text] [Related]  

  • 17. Cost-effectiveness analysis of olaparib maintenance therapy for BRCA mutation ovarian cancer in the public sector in Malaysia.
    Yong CM; Yehgambaram PAP; Lee SWH
    PLoS One; 2024; 19(2):e0298130. PubMed ID: 38300930
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States.
    Guy H; Walder L; Fisher M
    Pharmacoeconomics; 2019 Mar; 37(3):391-405. PubMed ID: 30478649
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of olaparib plus bevacizumab versus bevacizumab monotherapy in the maintenance of patients with homologous recombination deficiency-positive advanced ovarian cancer after response to first-line platinum-based chemotherapy.
    Cedillo S; Garí C; Aceituno S; Manso L; Cercos Lleti AC; Ventayol Bosch P; Casado A; Perez Fidalgo A
    Int J Gynecol Cancer; 2024 Feb; 34(2):277-284. PubMed ID: 38054270
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of olaparib versus routine surveillance in the maintenance setting for patients with
    Tan DS; Chan JJ; Hettle R; Ghosh W; Viswambaram A; Yu CC
    J Gynecol Oncol; 2021 Mar; 32(2):e27. PubMed ID: 33559410
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.